Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Treasury Shares (2023 - 2025)

Historic Treasury Shares for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $73.4 million.

  • BioLineRx's Treasury Shares rose 11326.75% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 11326.75%. This contributed to the annual value of $38.1 million for FY2024, which is 2150.22% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Treasury Shares is $73.4 million, which was up 11326.75% from $71.8 million recorded in Q2 2025.
  • BioLineRx's 5-year Treasury Shares high stood at $73.4 million for Q3 2025, and its period low was $27.1 million during Q1 2023.
  • Over the past 3 years, BioLineRx's median Treasury Shares value was $34.4 million (recorded in 2024), while the average stood at $41.8 million.
  • As far as peak fluctuations go, BioLineRx's Treasury Shares soared by 1570.11% in 2024, and later soared by 11326.75% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Treasury Shares stood at $31.4 million in 2023, then increased by 21.5% to $38.1 million in 2024, then surged by 92.74% to $73.4 million in 2025.
  • Its Treasury Shares was $73.4 million in Q3 2025, compared to $71.8 million in Q2 2025 and $62.6 million in Q1 2025.